Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CDI Launches iCell® DopaNeurons, Neural Floor Plate-derived Midbrain Dopaminergic Neurons

Published: Wednesday, April 30, 2014
Last Updated: Thursday, May 01, 2014
Bookmark and Share
Cells Provide a More Relevant In Vitro Model for Neurological Disorders, including Parkinson’s Disease and Schizophrenia.

Cellular Dynamics International, Inc. today announced the launch of iCell® DopaNeurons, the company’s neural floor plate-derived midbrain dopaminergic neurons generated from human induced pluripotent stem cells (iPSCs).

Key points:

•       Dopaminergic neurons, specifically those located in the floor plate-derived midbrain, are implicated in neurological disorders such as Parkinson’s disease and schizophrenia; thus iCell DopaNeurons provide a highly relevant in vitro model to investigate these types of pathologies.

•       Midbrain dopaminergic neurons develop from an early developmental stage of the brain called the floor plate. Other commercially available iPSC-derived dopaminergic neurons do not follow this developmental path, but instead are derived from neural stem cells. Only midbrain dopaminergic neurons have been shown to be engraftable in animals (1), indicating the promise for the development of cell-based therapies.

•       In addition to iCell DopaNeurons, CDI’s MyCell® process can be applied to develop and manufacture cells from donors with dopaminergic neuron-based diseases.

•       CDI exclusively licensed the technology, invented by Lorenz Studer, M.D., and his laboratory team at Memorial Sloan Kettering Cancer Center, to create floor-plate-derived midbrain dopaminergic neurons for use in research.

Quotes:
Lorenz Studer, M.D., director, Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Center, said, “We are pleased that Cellular Dynamics has licensed our technology to create dopaminergic neurons for research use that are specific to the substantia nigra, the small area of the brain implicated in Parkinson’s disease. Research in our laboratory has shown that iPSC-derived dopaminergic neurons that follow the midbrain dopaminergic developmental pathway are able to engraft in animal models for Parkinson’s disease. We’re excited that CDI will make these cells widely available for research purposes, enabling researchers to better understand dopaminergic neuron-based diseases and work toward possible patient therapies.”

Chris Parker, chief commercial officer of CDI, said, “Despite decades of effort and resources applied by pharmaceutical companies to treat diseases such as Parkinson’s, there are no cures available. iCell DopaNeurons now offer a human in vitro system that we believe more closely reflects human biology than other model systems available today. CDI’s manufacturing capabilities enable these specialized neurons to be developed at a high purity and quantity with rigorous quality control so that researchers studying dopaminergic diseases have a stable supply source of a relevant in vitro model.”



Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cord Blood Registry and CDI Announce Collaboration
Collaboration to reprogram newborn stem cells into induced pluripotent stem cells.
Wednesday, January 14, 2015
Using iPSC-derived Cells to Coat Blood Vessels in Kidney Scaffolds
Cellular Dynamics and Northwestern University take first steps toward rebuilding an organ using manufactured human cells.
Tuesday, November 18, 2014
Cellular Dynamics International Reports Third Quarter 2014 Financial Results
Cellular Dynamics International, Inc. reported financial results for the third quarter and nine months ended September 30, 2014.
Tuesday, November 11, 2014
Cellular Dynamics Awarded $1.2 M NEI Contract
Contract will see company develop patient-derived stem cells in gear-up for age-related macular degeneration trial.
Tuesday, October 28, 2014
Cellular Dynamics Awarded NEI Contract
Contract awarded for the development of patient-derived stem cells in gear-up for age-related macular degeneration trial.
Monday, October 27, 2014
Cellular Dynamics Awarded U.S. Patent
Patent strengthens CDI’s position as leading manufacturer of human cells for research and clinical applications.
Friday, August 29, 2014
Cellular Dynamics Awarded Pluripotent Stem Cells Patents
Patents secure CDI’s position as leading manufacturer of human cells from most common, easily accessible donor source for research, drug discovery and regenerative medicine.
Thursday, July 10, 2014
Cellular Dynamics Q4 Revenues Increase 41%
Cellular Dynamics International, Inc. reported financial results for the fourth quarter and for the fiscal year ended December 31, 2013.
Tuesday, March 11, 2014
Cellular Dynamics Signs Agreement with Nestlé Institute of Health Sciences
Agreement will see company to supply iCell® and MyCell® products for nutritional research.
Wednesday, January 08, 2014
The Hamner Institutes and Cellular Dynamics Collaborate
The parties will develop predictive in vitro screening assays for chemical, environmental and pharmaceutical toxicology assessments.
Monday, December 09, 2013
Jain Foundation Signs Agreement with Cellular Dynamics
Company will create iPSC lines from patients with muscular dystrophies for use as disease models for basic research and drug discovery.
Wednesday, December 04, 2013
CDI Reports Third Quarter 2013 Financial Results
Revenues more than double.
Wednesday, November 13, 2013
Cellular Dynamics Receives Formal Notice of Grant Award (NGA) for $16 Million Stem Cell Banking Project
NGA signifies entry into a definitive agreement and initiation of funding.
Tuesday, November 05, 2013
Cellular Dynamics Issued U.S. Patent
The patent relates to the method by which induced pluripotent stem cells are differentiated into the diverse types of endothelial and hematopoietic cells.
Thursday, October 17, 2013
Cellular Dynamics International Announces Closing of Initial Public Offering
Company announced the closing of its previously announced initial public offering of 3,846,000 shares of common stock at a price to the public of $12.00 per share.
Wednesday, July 31, 2013
Scientific News
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Stem Cells Rescue Patients from Mitochondrial Disease
A study led by OHSU researchers has revealed a critical first step in developing a new gene and stem cell regenerative technique for treating patients with mitochondrial disease.
Eco-Friendly Nanobullet to Battle Bacteria
Researchers have developed a method to combat bacteria by engineering nanoscale particles that add the antimicrobial potency of silver to a core of lignin, a ubiquitous substance found in all plant cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!